The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia/death rates with a 50 mg/m2 biweekly docetaxel regimen. Despite a higher cumulative docetaxel dose ...
Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial consultant. She has a demonstrated history of working in both institutional and retail environments, from broker-dealers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback